<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459159</url>
  </required_header>
  <id_info>
    <org_study_id>TLK199.2108</org_study_id>
    <nct_id>NCT01459159</nct_id>
  </id_info>
  <brief_title>Study of (Telintra速) in Non-Del(5q) Myelodysplastic Syndrome</brief_title>
  <official_title>Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra速) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Telik</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Telik</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, single arm open label Phase 2b Study of oral ezatiostat (Telintra速) in
      Patients who are RBC tranfusion dependent, Low to INT-1 IPSS risk, non-del (5q)
      Myelodysplastic Syndrome (MDS).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study TLK199.2108 was terminated for business reasons.
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematologic Improvement-Erythroid (HI-E) rate</measure>
    <time_frame>At 8 weeks of treatment</time_frame>
    <description>Hematologic Improvement response will be assessed per the IWG MDS response criteria (2006)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematologic Improvement-Erythroid (HI-E) rate</measure>
    <time_frame>At 16 weeks of treatment</time_frame>
    <description>Hematologic Improvement response will be assessed per the IWG MDS response criteria (2006)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematologic Improvement-Erythroid (HI-E) rate</measure>
    <time_frame>At 24 weeks of treatment</time_frame>
    <description>Hematologic Improvement response will be assessed per the IWG MDS response criteria (2006)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematologic Improvement-Erythroid (HI-E) rate</measure>
    <time_frame>At 32 weeks of treatment</time_frame>
    <description>Hematologic Improvement response will be assessed per the IWG MDS response criteria (2006)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RBC Transfusion independence (TI) rate</measure>
    <time_frame>At 4, 8, 12, 16, 20, 24, 28 &amp; 32 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Improvement-Neutrophil (HI-N) rate</measure>
    <time_frame>At 8, 16, 24, &amp; 32 weeks of treatment</time_frame>
    <description>Hematologic Improvement response will be assessed per the IWG MDS response criteria (2006)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Improvement-Platelet (HI-P) rate</measure>
    <time_frame>At 8, 16, 24, &amp; 32 weeks of treatment</time_frame>
    <description>Hematologic Improvement response will be assessed per the IWG MDS response criteria (2006)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unilineage, bilineage, trilineage, and overall HI response rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytogenetic response rate</measure>
    <time_frame>16 weeks, 48 weeks and at the time of first HI response</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of ezatiostat in this MDS population</measure>
    <time_frame>At 4, 8, 12, 16, 20, 24, 28 &amp; 32 weeks of treatment</time_frame>
    <description>Recording and grading of AEs using NCI-CTCAE v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the relationship between HI-E response, gene expression profiling and response-related variables</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezatiostat hydrochloride (Telintra速)</intervention_name>
    <description>Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.</description>
    <other_name>Telintra</other_name>
    <other_name>Telintra Tablets</other_name>
    <other_name>Oral Telintra</other_name>
    <other_name>ezatiostat</other_name>
    <other_name>ezatiostat hydrochloride</other_name>
    <other_name>oral ezatiostat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary or de Novo MDS

          -  Low to Intermediate-1 IPSS risk of MDS

          -  ECOG performance score of 0 or 1

          -  Documentation of significant anemia with or without additional cytopenia

          -  Adequate kidney and liver function

          -  Patients must have discontinued hematopoietic growth factors at least 3 weeks prior to
             study entry

        Exclusion Criteria:

          -  Deletion of the 5q chromosome [del(5q) MDS]

          -  Prior allogenic bone marrow transplant for MDS

          -  Known sensitivity to ezatiostat (injection or oral tablets)

          -  Prior treatment with hypomethylating agent (HMA) (e.g., azacitadine, decitabine)

          -  History of MDS IPSS risk score of greater than 1.0

          -  Pregnant or lactating women

          -  Any severe concurrent disease, infection or comorbidity that, in the judgement of the
             investigator, would make the patient inappropriate for study entry

          -  Oral steroids greater than 10 mg per day. Exceptions: those prescribed for other
             conditions (such as new adrenal failure, asthma, arthritis) or brief sterioid use
             (such as tapered dosing for an acute non-MDS condition)

          -  History of hepatitis B or C, or HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail L Brown, MD</last_name>
    <role>Study Director</role>
    <affiliation>Telik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bay Area Cancer Research Group</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SIU School of Medicine, Simmons Cancer Institute</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>October 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2011</study_first_posted>
  <last_update_submitted>November 20, 2013</last_update_submitted>
  <last_update_submitted_qc>November 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematology</keyword>
  <keyword>MDS</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Low risk MDS</keyword>
  <keyword>Int-1 risk MDS</keyword>
  <keyword>Transfusion dependence</keyword>
  <keyword>Telintra</keyword>
  <keyword>ezatiostat</keyword>
  <keyword>ezatiostat hydrochloride</keyword>
  <keyword>TLK199</keyword>
  <keyword>Glutathione</keyword>
  <keyword>Glutathione analog</keyword>
  <keyword>Glutathione Transferase</keyword>
  <keyword>Glutathione Transferase P1-1 inhibitor</keyword>
  <keyword>GST P1-1 inhibitor</keyword>
  <keyword>Apoptosis</keyword>
  <keyword>Differentiation</keyword>
  <keyword>Enzyme inhibitor</keyword>
  <keyword>non-del (5q)</keyword>
  <keyword>non-deletion 5q</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

